多系统缩中的疾病进展:ASPIRE多模式生物标志物研究
Margherita Fabbri1,2,3, Natalia Del Campo1, Wassilios G Meissner4,5
1Clinical Investigation Center CIC1436, Department of Clinical Pharmacology and Neurosciences, Parkinson Expert Centre and NeuroToul Center of Excellence in Neurodegeneration (COEN) of Toulouse; INSERM, University of Toulouse, CHU of Toulouse, Toulouse, France.
早期多重系统缩 (MSA) 显示神经成像在六个月内发生快速变化. 较高的神经丝轻链 (NfL) 水平预测MSA患者的死亡率和学风险增加.
科学领域:
- 神经学
- 生物标志物研究
- 神经退行性疾病
背景情况:
- 多重系统缩 (MSA) 是一种渐进的神经退行性疾病.
- 早期诊断和了解疾病进展对于患者的治疗至关重要.
- 候选生物标志物需要在早期MSA中进行表征.
研究的目的:
- 在早期多重系统缩 (MSA) 中描述候选生物标志物的变化.
- 确定MSA疾病更快进展的基线预测因素.
- 评估神经成像和血NfL在早期MSA中的有用性.
主要方法:
- 一年期前性多中心研究,涉及早期MSA患者和健康对照.
- 评估的临床分数 (UMSARS),3T-MRI,DaT-SPECT,以及血NfL.
- 使用混合线性回归分析了从基线到6个月和12个月的变化.
主要成果:
- 在6个月内观察到UMSARS得分显著恶化和脑干/大脑缩的增加.
- 在MSA-P和MSA-C亚型中发现了较低的条纹特异结合比率 (SBR).
- 预测临床恶化;较高的血NfL与中断和死亡风险相关.
结论:
- 在早期的MSA中,神经影像变化可以在6个月内检测到.
- 血NfL是MSA死亡率和退学风险的重要预测因素.
- 纵向生物标志物评估为MSA进展提供了有价值的见解.
更多相关视频
07:08A High Throughput, Multiplexed and Targeted Proteomic CSF Assay to Quantify Neurodegenerative Biomarkers and Apolipoprotein E Isoforms Status
Published on: October 20, 2016
09:47Author Spotlight: Advancing Alzheimer's Research – Exploring Early Detection and Multi-Omics Approaches
Published on: December 15, 2023
相关概念视频
Tumor Progression
Colon cancer is one of the best-documented examples of tumor progression. Early mutation in the APC gene in colon cells causes a small growth on the colon wall called a polyp. With time, this polyp grows into a benign, pre-cancerous tumor. Further...
Myasthenia Gravis: Diagnostic Tests
The edrophonium test is a diagnostic tool for myasthenia gravis. It involves...
Acute Coronary Syndrome III: Diagnostic Studies
Atherosclerosis II: Clinical Manifestations and Diagnostic Tests
Atherosclerosis III: Management
Peripheral Arterial Disease II: Clinical Manifestations and Diagnostic Evaluation
